blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3237010

EP3237010 - FORMULATION OF HYPERICIN FOR PHOTODYNAMIC THERAPY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.07.2020
Database last updated on 27.07.2024
FormerThe patent has been granted
Status updated on  12.07.2019
FormerGrant of patent is intended
Status updated on  27.05.2019
FormerExamination is in progress
Status updated on  19.10.2018
FormerRequest for examination was made
Status updated on  29.09.2017
FormerThe international publication has been made
Status updated on  08.04.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Sanochemia Pharmazeutika AG
Boltzmanngasse 11
1090 Wien / AT
[2017/44]
Inventor(s)01 / ABRAHAMSBERG, Christina
Charasgasse 3/31
1030 Wien / AT
02 / FRANTSITS, Werner
Nothartgasse 19
1130 Wien / AT
03 / GERDES, Klaus
Antoniusstrasse 20
41564 Kaarst Vorst / DE
04 / GUNGL, Jòzsef
Kosbor Utca 19
9423 Àgfalva / HU
05 / KÄLZ, Beate
Gartengasse 11
7035 Steinbrunn / AT
06 / MEDINGER, Gregor
POB 1176
10 Elizabeth Street
Sag Harbor, NY 11963 / US
07 / WELZIG, Stefan
Boerhaavegasse 8A/2/6.17
1030 Wien / AT
 [2018/24]
Former [2017/44]01 / ABRAHAMSBERG, Christina
Charasgasse 3/31
1030 Wien / AT
02 / FRANTSITS, Werner
Nothartgasse 19
1130 Wien / AT
03 / GERDES, Klaus
Behrenstrasse 25
40233 De / DE
04 / GUNGL, Jòzsef
Kosbor Utca 19
9423 Àgfalva / HU
05 / KÄLZ, Beate
Gartengasse 11
7035 Steinbrunn / AT
06 / MEDINGER, Gregor
POB 1176
10 Elizabeth Street
Sag Harbor, NY 11963 / US
07 / WELZIG, Stefan
Boerhaavegasse 8A/2/6.17
1030 Wien / AT
Representative(s)Beer & Partner Patentanwälte KG
Lindengasse 8
1070 Wien / AT
[2017/44]
Application number, filing date16718843.207.04.2016
[2017/44]
WO2016AT00033
Priority number, dateAT2015000063028.09.2015         Original published format: AT 6302015
[2017/44]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report
No.:WO2017054017
Date:06.04.2017
Language:DE
[2017/14]
Type: A1 Application with search report 
No.:EP3237010
Date:01.11.2017
Language:DE
The application published by WIPO in one of the EPO official languages on 06.04.2017 takes the place of the publication of the European patent application.
[2017/44]
Type: B1 Patent specification 
No.:EP3237010
Date:14.08.2019
Language:DE
[2019/33]
Search report(s)International search report - published on:EP06.04.2017
ClassificationIPC:A61K41/00, A61K47/58, A61K47/60, A61P35/00, A61K9/00, A61K9/08, A61K9/19, A61K47/32
[2019/21]
CPC:
A61K41/0057 (EP,KR,US); A61K9/08 (EP,KR,US); A61K47/10 (KR);
A61K47/32 (EP,KR,US); A61K47/58 (EP,KR,US); A61K47/60 (EP,KR,US);
A61K9/0009 (EP,KR,US); A61K9/19 (EP,KR,US); A61N5/062 (KR,US);
A61P13/10 (EP); A61P17/00 (EP); A61P35/00 (EP);
A61P43/00 (EP); A61N2005/0663 (KR,US) (-)
Former IPC [2017/44]A61K41/00, A61P35/00, A61K9/00, A61K9/08, A61K47/32
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/44]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:FORMULIERUNG VON HYPERICIN ZUR PHOTODYNAMISCHEN THERAPIE[2017/44]
English:FORMULATION OF HYPERICIN FOR PHOTODYNAMIC THERAPY[2017/44]
French:FORMULATION D'HYPÉRICINE POUR LA THÉRAPIE PHOTODYNAMIQUE[2017/44]
Entry into regional phase27.04.2017National basic fee paid 
27.04.2017Designation fee(s) paid 
27.04.2017Examination fee paid 
Examination procedure27.04.2017Amendment by applicant (claims and/or description)
27.04.2017Examination requested  [2017/44]
27.04.2017Date on which the examining division has become responsible
22.10.2018Despatch of a communication from the examining division (Time limit: M04)
21.02.2019Reply to a communication from the examining division
28.05.2019Communication of intention to grant the patent
05.07.2019Fee for grant paid
05.07.2019Fee for publishing/printing paid
05.07.2019Receipt of the translation of the claim(s)
Opposition(s)03.06.2020No opposition filed within time limit [2020/32]
Fees paidRenewal fee
22.02.2018Renewal fee patent year 03
24.04.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.04.2016
AL14.08.2019
CY14.08.2019
CZ14.08.2019
EE14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
MC14.08.2019
MK14.08.2019
MT14.08.2019
RO14.08.2019
RS14.08.2019
SI14.08.2019
SK14.08.2019
SM14.08.2019
BG14.11.2019
IS14.12.2019
PT16.12.2019
LU07.04.2020
[2022/32]
Former [2022/28]HU07.04.2016
AL14.08.2019
CY14.08.2019
CZ14.08.2019
EE14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
MC14.08.2019
MT14.08.2019
RO14.08.2019
RS14.08.2019
SI14.08.2019
SK14.08.2019
SM14.08.2019
BG14.11.2019
IS14.12.2019
PT16.12.2019
LU07.04.2020
Former [2021/08]AL14.08.2019
CZ14.08.2019
EE14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
MC14.08.2019
RO14.08.2019
RS14.08.2019
SI14.08.2019
SK14.08.2019
SM14.08.2019
BG14.11.2019
IS14.12.2019
PT16.12.2019
LU07.04.2020
Former [2020/52]AL14.08.2019
CZ14.08.2019
EE14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
MC14.08.2019
RO14.08.2019
RS14.08.2019
SI14.08.2019
SK14.08.2019
SM14.08.2019
BG14.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/37]AL14.08.2019
CZ14.08.2019
EE14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
RO14.08.2019
RS14.08.2019
SI14.08.2019
SK14.08.2019
SM14.08.2019
BG14.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/36]AL14.08.2019
CZ14.08.2019
EE14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
RO14.08.2019
RS14.08.2019
SK14.08.2019
SM14.08.2019
BG14.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/27]AL14.08.2019
CZ14.08.2019
EE14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
RO14.08.2019
RS14.08.2019
SK14.08.2019
SM14.08.2019
BG14.11.2019
PT16.12.2019
IS24.02.2020
Former [2020/26]AL14.08.2019
CZ14.08.2019
EE14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
RO14.08.2019
RS14.08.2019
SK14.08.2019
BG14.11.2019
PT16.12.2019
IS24.02.2020
Former [2020/24]AL14.08.2019
EE14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
RO14.08.2019
RS14.08.2019
BG14.11.2019
PT16.12.2019
IS24.02.2020
Former [2020/23]AL14.08.2019
EE14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
RO14.08.2019
RS14.08.2019
BG14.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/22]AL14.08.2019
EE14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
RS14.08.2019
BG14.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/15]AL14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
RS14.08.2019
BG14.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/12]HR14.08.2019
LT14.08.2019
LV14.08.2019
RS14.08.2019
BG14.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/10]LT14.08.2019
BG14.11.2019
PT16.12.2019
Former [2020/08]LT14.08.2019
Cited inInternational search[AD]WO0189576  (KUBIN ANDREAS [AT], et al) [AD] 1-10 * page 2, paragraph 2 - paragraph 3 * * page 4, paragraph 3 ** page 5, paragraph 4 - page 6, paragraph 3 *;
 [XYI]WO2009066294  (HY BIOPHARMA INC [US], et al) [X] 1-3,5-8,10 * page 4, line 3 - line 13 * * page 8, line 2 - line 24 * * examples 1, 2 * [Y] 4 [I] 9;
 [XYI]WO2015131891  (BRIU GMBH [DE]) [X] 1-3,5,6,8 * page 7, line 30 - page 8, line 16 * * page 5, line 19 - line 33 * * page 2, line 13 - line 29 * [Y] 4 [I] 9;
 [XI]  - HUYGENS A ET AL, "Stability of different formulations and ion pairs of hypericin", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 59, no. 3, ISSN 0939-6411, (20050401), pages 461 - 468, (20050401), XP027805033 [X] 1,2,5-8,10 * abstract * * page 462, column 2, paragraph 1 * * figure 4 * [I] 9
 [Y]  - ANDREAS KUBIN ET AL, "Fluorescence Diagnosis of Bladder Cancer with New Water Soluble Hypericin Bound to Polyvinylpyrrolidone: PVP-Hypericin", PHOTOCHEMISTRY AND PHOTOBIOLOGY, US, (20081101), vol. 84, no. 6, doi:10.1111/j.1751-1097.2008.00384.x, ISSN 0031-8655, pages 1560 - 1563, XP055285844 [Y] 4 * abstract * * page 1561, column 1, paragraph 3 - paragraph 4 *

DOI:   http://dx.doi.org/10.1111/j.1751-1097.2008.00384.x
 [A]  - DANIELA FEINWEBER ET AL, "Applicability of new degradable hypericin-polymer-conjugates as photosensitizers: principal mode of action demonstrated by in vitro models", PHOTOCHEMICAL AND PHOTOBIOLOGICAL SCIENCES, GB, (20140101), vol. 13, no. 11, doi:10.1039/C4PP00251B, ISSN 1474-905X, pages 1607 - 1620, XP055286452 [A] 1-10 * abstract * * page 1608, column 1, paragraph 2 - paragraph 5 * * figures 1,2 * * page 1618, column 1, paragraph 3 - column 2, paragraph 3 *

DOI:   http://dx.doi.org/10.1039/C4PP00251B
 [AD]  - JOACHIM VANDEPITTE ET AL, "Biodistribution of PVP-hypericin and hexaminolevulinate-induced PpIX in normal and orthotopic tumor-bearing rat urinary bladder", CANCER CHEMOTHERAPY AND PHARMACOLOGY., BERLIN., (20110401), vol. 67, no. 4, doi:10.1007/s00280-010-1375-0, ISSN 0344-5704, pages 775 - 781, XP055286423 [AD] 1-10 * abstract * * page 777, column 1, paragraph 2 * * page 780, column 1, paragraph 5 - column 2, paragraph 1 *

DOI:   http://dx.doi.org/10.1007/s00280-010-1375-0
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.